The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010 KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet Drug safety 37, 283-294, 2014 | 148 | 2014 |
The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010 KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet Drug safety 37, 283-294, 2014 | 148 | 2014 |
Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) KB Hoffman, AR Demakas, M Dimbil, NP Tatonetti, CB Erdman Drug safety 37, 971-980, 2014 | 73 | 2014 |
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012 KB Hoffman, A Demakas, CB Erdman, M Dimbil, PM Doraiswamy Bmj 347, 2013 | 38 | 2013 |
A drug safety rating system based on postmarketing costs associated with adverse events and patient outcomes KB Hoffman, M Dimbil, RF Kyle, NP Tatonetti, CB Erdman, A Demakas, ... Journal of Managed Care & Specialty Pharmacy 21 (12), 1134-1143c, 2015 | 10 | 2015 |
System and method for surveillance and evaluation of safety risks associated with medical interventions KB Hoffman, BM Overstreet, CB Erdman, R Kyle US Patent App. 14/279,105, 2014 | 7 | 2014 |
Post-approval adverse events of new and old anticoagulants KB Hoffman, A Demakas, CB Erdman, M Dimbil BMJ 348, 2014 | 3 | 2014 |
System and Method for Surveillance and Evaluation of Safety Risks Associated with Medical Interventions KB Hoffman, BM Overstreet, CB Erdman, R Kyle US Patent App. 14/752,452, 2015 | 2 | 2015 |
Neuropsychiatric adverse effects in FDA reporting system A VULGARIS BMJ 347, 21, 2013 | | 2013 |
Tamiflu correspondence with Roche KB Hoffman, A Demakas, CB Erdman, M Dimbil, P Murali | | 2013 |